CJC-1295 (no DAC / Mod GRF 1-29)
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
CJC-1295 (no DAC / Mod GRF 1-29) is listed as endocrine / ghrh analog.
- •Physiologic GH pulse amplification
- •Anti-aging
- •Sleep quality
Regulatory status: Not FDA-approved; compounded/research use.
Structure & Properties
Compound: CJC-1295 (no DAC / Mod GRF 1-29); also known as Mod GRF 1-29, CJC-1295 no DAC.
Pharmacologic class: Endocrine / GHRH Analog.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Short-acting GHRH analog (t½ ~30 min) — preserves pulsatile GH secretion; often combined with Ipamorelin for synergy.
- •Preserves natural GH pulsatility
- •Improved sleep and recovery (anecdotal)
- •Synergistic with GHRPs
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Pre-clinical and observational only
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
2–3× daily on an empty stomach — typical schedule is post-workout, mid-day, and 30 min pre-bed. Avoid food (fats/carbs) 30 min before and after each dose to preserve the GH pulse.
Potential interactions and combinations to avoid
- •CJC-1295 with DAC — same class, do not stack
- •Tesamorelin — redundant GHRH activity
- •Food or alcohol within 30 min of dosing
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Water retention
- •Headache
- •IGF-1 elevation
- •Theoretical oncogenicity
Contraindications
- •Active malignancy
- •Pregnancy
- •Severe diabetic retinopathy
- •Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- •Active or untreated diabetic retinopathy
- •Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- •Untreated hypothyroidism or uncorrected adrenal insufficiency
- •Acromegaly, pituitary adenoma, or intracranial hypertension
- •Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- •Critical illness after acute surgery, trauma, or respiratory failure
- •Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 100–300 mcg/dose
Frequency: 2–3× daily or before sleep
Cycling: 8–12 weeks on / 4 weeks off.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Ipamorelin or GHRP-2 — classic GHRH + GHRP synergy
- •BPC-157 for injury cycles
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is CJC-1295 (no DAC / Mod GRF 1-29)?
In plain words
CJC-1295 without DAC is a modified version of a hormone signal that prompts growth hormone release. The body clears it relatively quickly, while it boosts the body's natural bursts of growth hormone. Researchers study it to see how it strengthens those bursts. Evidence is limited; risks include water retention, headache, and increased IGF-1 [a growth-related hormone], with a theoretical concern about cancer promotion.
Technical definition
CJC-1295 without DAC, also called Mod GRF 1-29, is a modified 29-amino-acid peptide analog of growth hormone–releasing hormone (GHRH). It acts at the GHRH receptor to amplify pulsatile growth hormone (GH) secretion and is short-acting, with a half-life of approximately 30 minutes. It is not FDA-approved; its status is compounded/research use, with preclinical and observational evidence.
Function
Dosing
Recommended Time of Day
Morning fasted, post-workout, and 30 min before bed — always on an empty stomach.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
8–12 weeks on / 4 weeks off.
Timing & Interactions
- ·CJC-1295 with DAC — same class, do not stack
- ·Tesamorelin — redundant GHRH activity
- ·Food or alcohol within 30 min of dosing
- ·Ipamorelin or GHRP-2 — classic GHRH + GHRP synergy
- ·BPC-157 for injury cycles
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on CJC-1295 (no DAC / Mod GRF 1-29) and sync them to Vial Lab.
Benefits
- ·Preserves natural GH pulsatility
- ·Improved sleep and recovery (anecdotal)
- ·Synergistic with GHRPs
Risks
- ·Water retention
- ·Headache
- ·IGF-1 elevation
- ·Theoretical oncogenicity
Contraindications
- ·Active malignancy
- ·Pregnancy
- ·Severe diabetic retinopathy
- ·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- ·Active or untreated diabetic retinopathy
- ·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- ·Untreated hypothyroidism or uncorrected adrenal insufficiency
- ·Acromegaly, pituitary adenoma, or intracranial hypertension
- ·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- ·Critical illness after acute surgery, trauma, or respiratory failure
- ·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Not FDA-approved; compounded/research use
Veterinary Use (Pets)
No established veterinary protocol for CJC-1295 (no DAC / Mod GRF 1-29). Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →